Moon AM, et al. - Researchers examined how DAA-induced sustained virologic response (SVR) is associated with posttreatment variceal bleeding. They followed 33,582 patients who initiated DAA-only anti-viral treatments in the United States Veterans Affairs healthcare system from 2013 to 2015, until 1 January 2019 for the development of gastro-oesophageal variceal bleeding defined by diagnostic codes. Variceal bleeding developed in 549 (1.6%) after treatment (mean follow-up 3.1 years). The analysis revealed the independent association of DAA-induced SVR with a lower risk of variceal bleeding during long-term follow-up in patients with and without pretreatment cirrhosis. Findings thereby illustrate an important real-world benefit of DAA treatment.